Navigation Links
Access Pharmaceuticals Presents New Data on the Company's Cobalamin(TM) Technology at an International Polymer Therapeutics Symposium
Date:5/28/2008

ored by a major pharmaceuticals company.

About Access:

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access' products include ProLindac(TM), currently in Phase 2 clinical testing of patients with ovarian cancer, and MuGard(TM) for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin(TM)-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism; Angiolix(R), a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is targeted to breast cancer; Prodrax(R), a non-toxic prodrug which is activated in the hypoxic zones of solid tumors to kill cancer cells; and Alchemix, a chemotherapeutic agent that combines multiple modes of action to overcome drug resistance. Access is also developing Phenylbutyrate ("PB"), an HDAC inhibitor and differentiating agent currently a Phase 2 clinical candidate. For additional information on Access Pharmaceuticals, please visit our website at http://www.accesspharma.com .

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our ability to close the financing transaction, early results from our clinical trial, Access' plans to continue and initiate clinical trials, the value of its products in the market, its ability to achieve clinical and commercial success and its ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited to Access' need to obtain additional financing in order to continue the clinical trial a
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program
2. Roche Gains Access to Important Oncology Target With Potential for Treating Major Cancers Such as Breast and Lung; First Drug Candidate in Phase I Clinical Testing
3. IDM Pharma Announces Availability of Mifamurtide (L-MTP-PE) Through Compassionate Access Study
4. Access Pharmaceuticals to Conduct Conference Call to Update Financial Community
5. Insmed Provides Update on IPLEX(TM) Expanded Access Program in Italy for the Treatment of Amyotrophic Lateral Sclerosis
6. Childrens Hospital Cancer Study Finds Adolescents and Young Adults Dont Get Same Access to Cutting-Edge Treatment as Younger Patients
7. Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin
8. New Analysis from 14 Countries Identifies Drug Access Priorities to Achieve 2010 AIDS Treatment Target
9. Demand for Spanish-Language Cancer Web Materials Quadruples; Internet Resources and Access Remain Scarce
10. Access Pharmaceuticals Announces Two Poster Presentations Reporting Significant Preclinical Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
11. Access Pharmaceuticals to Present Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...ccumetrics,Inc.,aprivately-helddeveloperandmarkete...o-usediagnosticsystemformeasuringanindividual,sres...andaspirin),announcedtodaythatTimothyI.Still,Presi...FinancialOfficerofAccumetrics,willbepresentingacor...eConferencebeingheldinNewYorkCityonDecember1-2,200...
(Date:11/24/2009).../--SpartaSystems,Inc.,themakerofTrackWisesoftwarea...olutions,todayannouncedthatSSLInternationalplc,ara...mpanyforgloballyrecognizedbrandssuchasDurexandScho...mentSystem(EQMS).ThecompanyisnowleveragingtheTrack...sthatincludeCorrectiveandPreventiveAction(CAPA)man...
(Date:11/24/2009)...SNewswire/--America,spharmaceuticalresearchandbiot...totreatorpreventHIV/AIDSandrelatedconditions,accor...searchandManufacturersofAmerica(PhRMA).December1ma...nesscampaignthatoriginatedatthe1988WorldSummitofMi..., "Wearegreatlyencouragedbythesecriticallyimportan...
Breaking Medicine Technology:Accumetrics to Present at the 21st Annual Piper Jaffray Health Care Conference 2SSL International plc Embraces TrackWise(R) Software for Global Quality and Compliance Efforts 2SSL International plc Embraces TrackWise(R) Software for Global Quality and Compliance Efforts 3New Report Shows 97 Medicines and Vaccines Currently in Development for HIV/AIDS 2New Report Shows 97 Medicines and Vaccines Currently in Development for HIV/AIDS 3Cardiac Science Appoints Healthcare Executive Ronald A Andrews Jr to Board of Directors 6032 1Cardiac Science Appoints Healthcare Executive Ronald A Andrews Jr to Board of Directors 6032 2Cardiac Science Appoints Healthcare Executive Ronald A Andrews Jr to Board of Directors 6032 3Cardiac Science Appoints Healthcare Executive Ronald A Andrews Jr to Board of Directors 6032 4Cardiac Science Appoints Healthcare Executive Ronald A Andrews Jr to Board of Directors 6032 5Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009 6029 1Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009 6029 2Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009 6029 3Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009 6029 4Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009 6029 5Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009 6029 6Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009 6029 7Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009 6029 8Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009 6029 9Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009 6029 10Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009 6029 11Trubion Pharmaceuticals Inc Reports Third Quarter and Nine Months 2009 Financial Results 6026 1Trubion Pharmaceuticals Inc Reports Third Quarter and Nine Months 2009 Financial Results 6026 2Trubion Pharmaceuticals Inc Reports Third Quarter and Nine Months 2009 Financial Results 6026 3Trubion Pharmaceuticals Inc Reports Third Quarter and Nine Months 2009 Financial Results 6026 4Trubion Pharmaceuticals Inc Reports Third Quarter and Nine Months 2009 Financial Results 6026 5Trubion Pharmaceuticals Inc Reports Third Quarter and Nine Months 2009 Financial Results 6026 6Trubion Pharmaceuticals Inc Reports Third Quarter and Nine Months 2009 Financial Results 6026 7
...CE V Drug Eluting Stent Demonstrates Clinically Me...y Endpoints, Including an 88 Percent Reduction in ...NDO, Fla., March 29 Long-term data presented toda... trial demonstrated that the clinical advantages o...t System continued to increase between two and thr...
..., March 28 Boston Scientific Corporation (NYSE: ... economic and quality of life outcomes, based on o...results found that while the overall cost effectiv...versus coronary artery bypass graft (CABG) surgery...was more cost effective than CABG in patients with...
Other Medicine Technology:Abbott's Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years 2Abbott's Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years 3Abbott's Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years 4Abbott's Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years 5SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(TM) Stents More Cost Effective Than Bypass Surgery in Many Patients With Complex Coronary Artery Disease 2SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(TM) Stents More Cost Effective Than Bypass Surgery in Many Patients With Complex Coronary Artery Disease 3SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(TM) Stents More Cost Effective Than Bypass Surgery in Many Patients With Complex Coronary Artery Disease 4SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(TM) Stents More Cost Effective Than Bypass Surgery in Many Patients With Complex Coronary Artery Disease 5
(Date:11/25/2009)..., WorkingTogethertoShareRecordsSafely,ImproveCar...--TheDepartmentofVeteransAffairs(VA)andKaiserPerma...ovecareandservicestoourNation,sheroes.VAandKaiserP...onichealthrecord(EHR)informationusingtheNationwide...ntofHealthandHumanServices. ,, "Theabilitytosha...
(Date:11/25/2009)..., GiftistheLargestDonationEverMadeinSupportofFeed....25/PRNewswire-USNewswire/--FeedingAmerica,thenati...da$1milliondonationfromtheBankofAmericaCharitableF...low-incomeAmericanswiththeSupplementalNutritionAss...ram.ThefundswillbeusedtohelpFeedingAmericafoodbank...
(Date:11/25/2009)...USTON - Two signaling pathways essential to normal...idermal growth factor receptor (EGFR) pathways - i...on and metastasis, researchers from The University...he Nov. 25 issue of Molecular Cell . , This new...ing components known to correlate with invasive ca...
(Date:11/25/2009)...ANGELES (Nov. 25, 2009) Melvin R. Kaplan, MD, FAC... the research institute that became Los Angeles Bi... Center (LA BioMed), will be honored by the Americ... to the care of patients. , At its April 22, 201...icians will present Dr. Kaplan with the Ralph O. C...
(Date:11/25/2009)...AS Nov. 25, 2009 Physicians at UT Southwestern M...ice designed to improve breathing in patients with... keep them from breathing independently. , UT S...one of only two sites in Texas and one of 25 in th..., called the NeuRx Diaphragm Pacing System. , Th...
Breaking Medicine News(10 mins):Health News:VA and Kaiser Permanente Invite Veterans to Participate in Health Record Pilot Program 2Health News:Bank of America Charitable Foundation Presents $1 Million Contribution to Feeding America in an Effort to Help Connect Low-Income Americans With Federal Nutrition Programs 2Health News:Bank of America Charitable Foundation Presents $1 Million Contribution to Feeding America in an Effort to Help Connect Low-Income Americans With Federal Nutrition Programs 3Health News:Crosstalk between critical cell-signaling pathways holds clues to tumor invasion and metastasis 2Health News:Crosstalk between critical cell-signaling pathways holds clues to tumor invasion and metastasis 3Health News:1 of LA BioMed's founders to be honored 2Health News:New device implanted by surgeons help paralyzed patients breathe easier 2
...finds that obesity increases the risk of death fro...e the overall risk a man will be diagnosed with th...ER, a peer-reviewed journal of the American Cancer...ate cancer. However, no such association was found...
...very adult these days knows that a diet laden with...r exercise and risky behaviors like smoking is a r...heart attacks. But a renowned heart disease resear...The fix is free. That’s because it costs nothing t...
...ed to test a medical device in a clinic at Clevela...tter to this effect was sent to U.S. Department of... A neurosurgeon was conducting an experiment to...zed subsequently. A letter describing this event h...
...vernment officials are worried about the lack of n...g women.// Previous research has linked the ... brain and spine. The research had also led to bre...1999 and 2004 showed that more than 50% of the 450...
...ducted by Dana-Farber Cancer Institute in Boston, ... chemotherapy drugs need to be monitored, prescrib... cases of unfortunate events, sourced from the ins... a consensus in the oncology field on standardized...
...s project, sponsored by the Canadian Institute of ...troke Foundation of Canada, have found that men an...ir heart disease. According to the study resul...usually effective in pinpointing heart problems in...
Other Medicine News:Health News:Excess Weight and Adult Weight Gain Increase Risk of Prostate Cancer Death 2Health News:Cure for Most Heart Attacks Is Free, but It's Important to Start Young 2Health News:Cure for Most Heart Attacks Is Free, but It's Important to Start Young 3Health News:Watchdog to Be Set on Oral Chemotherapy, Warns Experts 2
... Laboratories is a national reference laboratory a...earch and development. ARUP offers an extensive te... in clinical and anatomic pathology. Owned by the ...lude more than half of the nation's university tea...
... Laboratories is a national reference laboratory a...earch and development. ARUP offers an extensive te... in clinical and anatomic pathology. Owned by the ...lude more than half of the nation's university tea...
... Laboratories is a national reference laboratory a...earch and development. ARUP offers an extensive te... in clinical and anatomic pathology. Owned by the ...lude more than half of the nation's university tea...
... Laboratories is a national reference laboratory a...earch and development. ARUP offers an extensive te... in clinical and anatomic pathology. Owned by the ...lude more than half of the nation's university tea...
Medicine Products: